Hypertension in Women: Recent Advances and Lingering Questions

Hypertension

Volumn 70, Issue 1, 2017, Pages 19-26

  Ahmad, Amier ^a   Oparil, Suzanne ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ORAL CONTRACEPTIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; AWARENESS; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; MASKED HYPERTENSION; MATERNAL HYPERTENSION; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; WHITE COAT HYPERTENSION; WOMEN'S HEALTH; AGE; BLOOD PRESSURE; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; UNITED STATES;

AGE FACTORS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; PREVALENCE; UNITED STATES; WOMEN'S HEALTH;

EID: 85020430741     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.08317     Document Type: Article

References (72)

1. Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: Final Data for 2013. Natl Vital Stat Rep. 2016;64:1-119.
2. Gholizadeh L, Davidson P. More similarities than differences: an international comparison of CVD mortality and risk factors in women. Health Care Women Int. 2008;29:3-22. doi: 10.1080/07399330701723756.
3. Benjamin EJ, Blaha MJ, Chiuve SE, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603. doi: 10.1161/ CIR.0000000000000485.
4. Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011-2014. NCHS Data Brief. 2015;220:1-8.
5. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013;133:1-8.
6. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441-450. doi: 10.1161/CIRCULATIONAHA.115.018912.
7. Keyhani S, Scobie JV, Hebert PL, McLaughlin MA. Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension. 2008;51:1149-1155. doi: 10.1161/ HYPERTENSIONAHA.107.107342.
8. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374. doi: 10.1056/NEJMra060433.
9. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. Whitecoat hypertension: new insights from recent studies. Hypertension. 2013;62:982-987. doi: 10.1161/HYPERTENSIONAHA.113.01275.
10. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61. doi: 10.1161/HYPERTENSIONAHA.107.100727.
11. Hansen TW, Kikuya M, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Jeppesen J, Ibsen H, Imai Y, Staessen JA; IDACO Investigators. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a metaanalysis of 7,030 individuals. J Hypertens. 2007;25:1554-1564. doi: 10.1097/HJH.0b013e3281c49da5.
12. Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:778-786. doi: 10.7326/M15-2223.
13. Kagan A, Faibel H, Ben-Arie G, Granevitze Z, Rapoport J. Gender differences in ambulatory blood pressure monitoring profile in obese, overweight and normal subjects. J Hum Hypertens. 2007;21:128-134. doi: 10.1038/sj.jhh.1002118.
14. Banegas JR, Segura J, de la Sierra A, Gorostidi M, Rodríguez-Artalejo F, Sobrino J, de la Cruz JJ, Vinyoles E, del Rey RH, Graciani A, Ruilope LM; Spanish Society of Hypertension ABPM Registry Investigators. Gender differences in office and ambulatory control of hypertension. Am J Med. 2008;121:1078-1084. doi: 10.1016/j.amjmed.2008. 06.037.
15. Divisón-Garrote JA, Banegas JR, De la Cruz JJ, Escobar-Cervantes C, De la Sierra A, Gorostidi M, Vinyoles E, Abellán-Aleman J, Segura J, Ruilope LM. Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. J Am Soc Hypertens. 2016;10:714-723. doi: 10.1016/j.jash.2016.06.035.
16. Li Y, Wei FF, Thijs L, et al; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130:466-474. doi: 10.1161/CIRCULATIONAHA.113.004876.
17. O'Brien E, Parati G, Stergiou G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-1768. doi: 10.1097/ HJH.0b013e328363e964.
18. Salles GF, Reboldi G, Fagard RH, Cardoso CR, Pierdomenico SD, Verdecchia P, Eguchi K, Kario K, Hoshide S, Polonia J, de la Sierra A, Hermida RC, Dolan E, O'Brien E, Roush GC; ABC-H Investigators. Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. Hypertension. 2016;67:693-700. doi: 10.1161/HYPERTENSIONAHA.115.06981.
19. Yan B, Peng L, Han D, Sun L, Dong Q, Yang P, Zheng F, Ong H, Zeng L, Wang G. Blood pressure reverse-dipping is associated with early formation of carotid plaque in senior hypertensive patients. Medicine (Baltimore). 2015;94:e604. doi: 10.1097/MD.0000000000000604.
20. Perez-Lloret S, Toblli JE, Cardinali DP, Milei J. Gender differences in age-related increase of asleep blood pressure. Arch Gerontol Geriatr. 2010;50:319-322. doi: 10.1016/j.archger.2009.05.005.
21. Franklin SS, Thijs L, Asayama K, et al; IDACO Investigators. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033-2043. doi: 10.1016/j.jacc.2016.08.035.
22. Omboni S, Aristizabal D, De la Sierra A, et al; ARTEMIS (international Ambulatory blood pressure Registry: TEleMonitoring of hypertension and cardiovascular rISk project) Investigators. Hypertension types defined by clinic and ambulatory blood pressure in 14 143 patients referred to hypertension clinics worldwide. Data from the ARTEMIS study. J Hypertens. 2016;34:2187-2198. doi: 10.1097/HJH.0000000000001074.
23. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas. 2008;60:10-18. doi: 10.1016/j.maturitas.2008.02.008.
24. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affect Disord. 2003;74:67-83.
25. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998;98:1892-1897.
26. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. 2000;102:1139-1144.
27. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24:52-58. doi: 10.1038/ajh.2010.203.
28. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232. doi: 10.1161/HYPERTENSIONAHA.109.129882.
29. Wang YC, Shimbo D, Muntner P, Moran AE, Krakoff LR, Schwartz JE. Prevalence of masked hypertension among US adults with nonelevated clinic blood pressure. Am J Epidemiol. 2017;185:194-202. doi: 10.1093/ aje/kww237.
30. Peacock J, Diaz KM, Viera AJ, Schwartz JE, Shimbo D. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens. 2014;28:521-528. doi: 10.1038/jhh.2014.9.
31. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24:52-58. doi: 10.1038/ajh.2010.203.
32. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
33. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14-26. doi: 10.1111/jch.12237.
34. McManus R, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. BMJ. 2012;344:e181.
35. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. doi: 10.1016/S0140-6736(15)01225-8.
36. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis. Lancet. 2016;387:435-443. doi: 10.1016/S0140-6736(15)00805-3.
37. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, Messerli FH. Optimal systolic blood pressure target after SPRINT insights from a network meta-analysis of randomized trials [published online ahead of print January 19, 2017]. Am J Med. doi: 10.1016/j.amjmed.2017.01.004. http://www.amjmed.com/article/S0002-9343(17)30035-9/fulltext. Accessed May 2, 2017.
38. Wright JT Jr, Williamson JD, Whelton PK, et al.; for the SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med. 2015;373:2103-2116.
39. Wenger NK, Ferdinand KC, Bairey Merz CN, Walsh MN, Gulati M, Pepine CJ; American College of Cardiology Cardiovascular Disease in Women Committee. Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. Am J Med. 2016;129:1030-1036. doi: 10.1016/j.amjmed.2016.06.022.
40. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997;126:761-767.
41. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669-2680. doi: 10.1093/eurheartj/ehn427.
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
43. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S; ALLHAT Collaborative Research Group. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014;8:808-819. doi: 10.1016/j. jash.2014.08.003.
44. Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT Jr; ALLHAT Collaborative Research Group. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 2013;61:977-986. doi: 10.1161/HYPERTENSIONAHA.111.00213.
45. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163-2168. doi: 10.1097/01.hjh.0000249692.96488.46.
46. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille DA, Lyle PA, Okin PM, Dahlöf B, Oparil S. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51:1103-1108. doi: 10.1161/HYPERTENSIONAHA.107.105296.
47. Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, Yunis C, Svendsen K, Liebson PR, Elmer PJ. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 pt 1):8-14.
48. Roberts JM, August PA, Bakris G, et al; for the American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-1131.
49. Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol. 2015;172:R23-R30. doi: 10.1530/ EJE-14-0444.
50. Thomas HN, Evans GW, Berlowitz DR, Chertow GM, Conroy MB, Foy CG, Glasser SP, Lewis CE, Riley WT, Russell L, Williams O, Hess R; SPRINT Study Group. Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT). J Hypertens. 2016;34:1224-1231. doi: 10.1097/HJH.0000000000000911.
51. Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2017;177:67-76. doi: 10.1001/jamainternmed.2016.6821.
52. Izumi Y, Matsumoto K, Ozawa Y, Kasamaki Y, Shinndo A, Ohta M, Jumabay M, Nakayama T, Yokoyama E, Shimabukuro H, Kawamura H, Cheng Z, Ma Y, Mahmut M. Effect of age at menopause on blood pressure in postmenopausal women. Am J Hypertens. 2007;20:1045-1050. doi: 10.1016/j.amjhyper.2007.04.019.
53. Son WM, Sung KD, Cho JM, Park SY. Combined exercise reduces arterial stiffness, blood pressure, and blood markers for cardiovascular risk in postmenopausal women with hypertension. Menopause. 2017;24:262-268. doi: 10.1097/GME.0000000000000765.
54. Bonnema RA, McNamara MC, Spencer AL. Contraception choices in women with underlying medical conditions. Am Fam Physician. 2010;82:621-628.
55. Giribela CR, Consolim-Colombo FM, Nisenbaum MG, Moraes TL, Giribela AH, Baracat EC, Melo NR. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015;31:912-915. doi: 10.3109/09513590.2015.1062860.
56. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol. 2014;63:1815-1822. doi: 10.1016/j.jacc.2014.02.529.
57. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156:918-930. doi: 10.1016/j. ahj.2008.06.042.
58. Bokslag A, Teunissen PW, Franssen C, van Kesteren F, Kamp O, Ganzevoort W, Paulus WJ, de Groot CJ. Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life. Am J Obstet Gynecol. [Epub ahead of print]. doi: 10.1016/j.ajog.2017.02.015.
59. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, Melbye M, Boyd HA. Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy. JAMA. 2016;315:1026-1033. doi: 10.1001/jama.2016.1869.
60. Fraser A, Nelson SM, Macdonald-Wallis C, Sattar N, Lawlor DA. Hypertensive disorders of pregnancy and cardiometabolic health in adolescent offspring. Hypertension. 2013;62:614-620. doi: 10.1161/ HYPERTENSIONAHA.113.01513.
61. Alsnes IV, Vatten LJ, Fraser A, Bjørngaard JH, Rich-Edwards J, Romundstad PR, Åsvold BO. Hypertension in Pregnancy and Offspring Cardiovascular Risk in Young Adulthood: Prospective and Sibling Studies in the HUNT Study (Nord-Trøndelag Health Study) in Norway. Hypertension. 2017;69:591-598. doi: 10.1161/ HYPERTENSIONAHA.116.08414.
62. Geelhoed JJ, Fraser A, Tilling K, Benfield L, Davey Smith G, Sattar N, Nelson SM, Lawlor DA. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and Children. Circulation. 2010;122:1192-1199. doi: 10.1161/ CIRCULATIONAHA.110.936674.
63. Theilen LH, Fraser A, Hollingshaus MS, Schliep KC, Varner MW, Smith KR, Esplin MS. All-cause and cause-specific mortality after hypertensive disease of pregnancy. Obstet Gynecol. 2016;128:238-244. doi: 10.1097/ AOG.0000000000001534.
64. Ehrenthal DB, Maiden K, Rogers S, Ball A. Postpartum healthcare after gestational diabetes and hypertension. J Womens Health (Larchmt). 2014;23:760-764. doi: 10.1089/jwh.2013.4688.
65. Nijdam ME, Timmerman MR, Franx A, Bruinse HW, Numans ME, Grobbee DE, Bots ML. Cardiovascular risk factor assessment after pre-eclampsia in primary care. BMC Fam Pract. 2009;10:77. doi: 10.1186/1471-2296-10-77.
66. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;(2):CD002252.
67. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407-417. doi: 10.1056/NEJMoa1404595.
68. Magee LA, von Dadelszen P, Singer J, et al; CHIPS Study Group. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123:1143-1151. doi: 10.1111/1471-0528.13569.
69. Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012;30:981-993. doi: 10.1016/j. ajem.2011.06.040.
70. Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. BJOG. 2000;107:299-307.
71. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: metaanalysis. BMJ. 2003;327:955-960. doi: 10.1136/bmj.327.7421.955.
72. Rothberger S, Carr D, Brateng D, Hebert M, Easterling TR. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens. 2010;23:1234-1240. doi: 10.1038/ajh.2010.159.